查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587790

臨床試驗中心網路市場規模、佔有率和趨勢分析報告：2025-2030 年按治療領域、階段、最終用途、地區和細分市場進行的預測

Clinical Trial Investigative Site Network Market Size, Share & Trends Analysis Report By Therapeutic Areas (Oncology, Cardiology), By Phase (Phase I, Phase II), By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

臨床試驗站點網路市場的成長與趨勢：

根據 Grand View Research, Inc. 的最新報告，預計到 2030 年，全球臨床試驗站點網路市場規模將達到 137.6 億美元，2025 年至 2030 年複合年成長率為 7.85%。

藥物研發投資的增加、對新治療方法的需求增加以及與臨床試驗設施管理相關的併發症是推動該行業成長的一些主要因素。過去五年來，臨床試驗持續增加。例如，根據ClinicalTrials.gov的數據，2018年註冊的臨床試驗超過262,298項，截至2022年9月，註冊的臨床試驗超過399,518項。隨著研究經費的增加，臨床試驗預計將進一步成長。

預計這將推動大流行後的行業成長。人們越來越關注降低與臨床研究相關的成本。僱用臨床試驗中心網路來支持監管職能，提高參與者的註冊率，並協助資料管理和品質保證。它還提高了流程合規性並減少了每個臨床試驗中的流程問題，有助於更快地啟動臨床試驗並縮短臨床試驗持續時間。這些因素支持了對臨床實驗站點網路的需求。各國政府正積極嘗試透過提供扣除額來改善研究和發展。例如，2022年1月，印度政府宣布將為研發提供高達200%的加權平均稅額扣抵抵免。

這些措施預計將改善藥物研發活動並促進產業成長。根據 IQVIA 的腫瘤學趨勢報告，癌症臨床試驗在過去十年中持續增加。例如，2011年註冊了1,242項臨床試驗，截至2021年，已註冊2,335項臨床試驗。由於癌症盛行率不斷增加，癌症臨床試驗的數量預計將進一步增加。預計這將增加疫情後癌症臨床試驗中對臨床實驗站點網路的需求。

臨床試驗現場網路市場報告亮點

  • 以治療領域來看，癌症領域在2024年以35.1%的佔有率佔據市場主導地位。針對癌症的臨床試驗數量的增加是支持該領域成長的關鍵因素之一。
  • 第三階段的患者數量比其他階段更多，支持了臨床實驗現場網路的需求。
  • 按最終用途分類，CRO（合約委外研發機構）產業預計在預測期內複合年成長率最快。
  • 這是由於臨床實驗網路和 CRO 之間的臨床試驗合作夥伴關係數量不斷增加。
  • 亞太地區的臨床試驗外包正在增加，預計在預測期內複合年成長率最快。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章臨床試驗現場網路市場的變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 市場分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章臨床試驗設施網路市場：階段估計與趨勢分析

  • 細分儀表板
  • 全球臨床試驗站點網路市場：相變分析
  • 2018年至2030年分階段臨床試驗中心網路規模及趨勢分析
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第5章臨床試驗設施網路市場：治療領域的估計與趨勢分析

  • 細分儀表板
  • 全球臨床試驗中心網路市場：治療領域波動分析
  • 2018年至2030年全球臨床試驗中心網路規模及趨勢分析：依治療領域
  • 腫瘤學
  • 心臟病學
  • 中樞神經系統症狀
  • 疼痛管理
  • 內分泌
  • 其他

第6章臨床試驗設施網路市場：最終用途估計與趨勢分析

  • 細分儀表板
  • 全球臨床試驗站點網路市場；
  • 2018-2030 年全球臨床試驗中心網路規模與趨勢分析（依最終用途）
  • 製藥和生物製藥公司
  • 醫療設備公司
  • 其他

第7章臨床試驗設施網路市場：區域估計與趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 公司分類
  • 2024 年企業市場分析
  • 公司簡介
    • ICON Plc
    • Velocity Clinical Research
    • IQVIA Inc.
    • Elligo Health Research
    • WCG Clinical
    • ClinChoice
    • Access Clinical Trials Inc.
    • FOMAT Medical Research, Inc.
    • SGS Societe Generale de Surveillance SA.
    • KV Clinical Research
    • SMO-Pharmina
    • Xylem Research LLP
    • The Aurum Institute
Product Code: GVR-4-68039-986-6

Clinical Trial Investigative Site Network Market Growth & Trends:

The global clinical trial investigative site network market size is estimated to reach USD 13.76 billion by 2030, expanding at a CAGR of 7.85% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing investments in pharmaceutical R&D, increasing demand for new therapies and complications associated with site management of clinical trials are some of the major factors driving the growth of the industry. There has been a consistent rise the clinical trials in the last 5 years. For instance, according to ClinicalTrials.gov, over 262,298 trials were registered in 2018, whereas as of September 2022, over 399,518 trials were registered. The clinical trials are expected to grow even further as the funding for research improves.

This is expected to propel the growth of the industry post-pandemic. There is a growing focus on reducing the cost associated with clinical research. Hiring a clinical trial investigative site network supports the regulatory function, improves the enrollment of participants, assists in data management, and quality assurance. It increases process compliance, reduces process issues with each trial, and helps with faster trial initiations, and shorter trial timelines. These factors are supporting the demand for clinical investigative site networks. The governments are actively trying to improve R&D by providing tax deductions. For instance, in January 2022, the Indian government stated that it is providing a weighted average tax deduction of up to 200% in R&D.

Such initiatives are expected to improve the R&D activities on drugs and thus support industry growth. According to the IQVIA, report on oncology trends, clinical trials for cancer have been increasing for the last 10 years. For instance, in 2011, 1,242 trials were registered for cancer, and as of 2021, 2,335 trials were registered for cancer. The number of clinical trials for cancer is expected to rise even further owing to the growing prevalence of the disease. This is expected to improve the demand for clinical investigative site networks for cancer clinical trials post-pandemic.

Clinical Trial Investigative Site Network Market Report Highlights:

  • Based on therapeutic areas, the oncology segment dominated the market with a share of 35.1% in 2024. The growing number of clinical trials for cancer is one of the major factors supporting the segment growth
  • The phase III segment led the industry in 2024 with the maximum revenue share as this phase includes a greater number of patients than other phases, thus supporting the demand for clinical investigative site network
  • Based on end-use, the Contract Research Organizations (CROs) segment is anticipated to witness the fastest CAGR over the forecast perio
  • This is owing to the increasing number of partnerships among site networks and CROs for clinical studies
  • Asia Pacific is anticipated to register the fastest CAGR over the forecast period due to a rise in the outsourcing of clinical trials in this region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Clinical Trial Investigative Site Network Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Prevalence of Chronic Diseases
      • 3.2.1.2. Increasing Technological Advancements
      • 3.2.1.3. Increasing Partnerships and Collaborations
      • 3.2.1.4. Expansion of Decentralized Trials
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Rising Costs of Clinical Trials
      • 3.2.2.2. Limited Awareness and Training
      • 3.2.2.3. Data Privacy Concerns
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Clinical Trial Investigative Site Network Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Clinical Trial Investigative Site Network Market; Phase Movement Analysis
  • 4.3. Global Clinical Trial Investigative Site Network Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Clinical Trial Investigative Site Network Market: Therapeutic Areas Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Clinical Trial Investigative Site Network Market; Therapeutic Areas Movement Analysis
  • 5.3. Global Clinical Trial Investigative Site Network Size & Trend Analysis, by Therapeutic Areas, 2018 to 2030 (USD Million)
  • 5.4. Oncology
    • 5.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Cardiology
    • 5.5.1. Cardiology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. CNS Conditions
    • 5.6.1. CNS Conditions market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Pain management
    • 5.7.1. Pain management market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Endocrine
    • 5.8.1. Endocrine market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Clinical Trial Investigative Site Network Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Clinical Trial Investigative Site Network Market; End Use Movement Analysis
  • 6.3. Global Clinical Trial Investigative Site Network Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical & Biopharmaceutical Companies
    • 6.4.1. Pharmaceutical & biopharmaceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Medical Device Companies
    • 6.5.1. Medical device companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Clinical Trial Investigative Site Network Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. North America
    • 7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Competitive scenario
      • 7.3.2.3. Regulatory framework
      • 7.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Competitive scenario
      • 7.3.3.3. Regulatory framework
      • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamics
      • 7.3.4.2. Competitive scenario
      • 7.3.4.3. Regulatory framework
      • 7.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Competitive scenario
      • 7.4.5.3. Regulatory framework
      • 7.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Competitive scenario
      • 7.4.6.3. Regulatory framework
      • 7.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Competitive scenario
      • 7.4.7.3. Regulatory framework
      • 7.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Competitive scenario
      • 7.4.8.3. Regulatory framework
      • 7.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Competitive scenario
      • 7.4.9.3. Regulatory framework
      • 7.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Company Market Position Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. ICON Plc
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Service benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Velocity Clinical Research
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Service benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. IQVIA Inc.
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Service benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Elligo Health Research
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Service benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. WCG Clinical
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Service benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. ClinChoice
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Service benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Access Clinical Trials Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Service benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. FOMAT Medical Research, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Service benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. SGS Societe Generale de Surveillance SA.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Service benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. KV Clinical Research
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Service benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. SMO-Pharmina
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Service benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Xylem Research LLP
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Service benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. The Aurum Institute
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Service benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 4 Global Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 5 Global Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 6 Global Clinical Trial Investigative Site Network, by Region, 2018 - 2030 (USD Million)
  • Table 7 North America Clinical Trial Investigative Site Network, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 9 Global Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 10 North America Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 11 U.S. Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 12 U.S. Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 13 U.S. Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 14 Canada Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 15 Canada Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 16 Canada Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 17 Mexico Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 18 Mexico Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 19 Mexico Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 20 UK Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 21 UK Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 22 UK Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 23 Germany Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 24 Germany Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 25 Germany Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 26 France Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 27 France Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 28 France Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 29 Italy Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 30 Italy Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 31 Italy Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 32 Spain Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 33 Spain Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 34 Spain Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Sweden Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 36 Sweden Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 37 Sweden Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 38 Norway Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 39 Norway Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 40 Norway Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 41 Denmark Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 42 Denmark Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 43 Denmark Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 44 India Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 45 India Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 46 India Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 47 China Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 48 China Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 49 China Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 50 Japan Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 51 Japan Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 52 Japan Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 53 India Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 54 India Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 55 India Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 56 Australia Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 57 Australia Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 58 Australia Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 59 Thailand Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 60 Thailand Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 61 Thailand Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 62 South Korea Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 63 South Korea Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 64 South Korea Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 65 Brazil Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 66 Brazil Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 67 Brazil Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 68 Argentina Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 69 Argentina Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 70 Argentina Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 71 Saudi Arabia Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 72 Saudi Arabia Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 73 Saudi Arabia Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 74 UAE Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 75 UAE Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 76 UAE Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 77 Kuwait Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 78 Kuwait Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 79 Kuwait Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1. Information Procurement
  • Fig. 2. Primary Research Pattern
  • Fig. 3. Market Research Approaches
  • Fig. 4. Value Chain-Based Sizing & Forecasting
  • Fig. 5. Market Formulation & Validation
  • Fig. 6. Clinical Trial Investigative Site Network, Market Segmentation
  • Fig. 7. Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8. Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9. Porter's Five Forces Analysis
  • Fig. 10. PESTEL Analysis
  • Fig. 11. Regional Marketplace: Key Takeaways
  • Fig. 12. Global Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 13. Global Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 14. Global Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 15. Global Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 16. Global Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 17. Global Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 18. Global Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 19. Global Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 20. Global Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 21. Global Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 22. Global Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 23. Global Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 24. Global Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 25. North America Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 26. North America Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 27. North America Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 28. North America Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 29. North America Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 30. North America Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 31. North America Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 32. North America Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 33. North America Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 34. North America Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 35. North America Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 36. North America Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 37. North America Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 38. U.S. Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 39. U.S. Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 40. U.S. Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 41. U.S. Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 42. U.S. Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 43. U.S. Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 44. U.S. Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 45. U.S. Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 46. U.S. Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 47. U.S. Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 48. U.S. Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 49. U.S. Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 50. U.S. Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 51. Canada Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 52. Canada Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 53. Canada Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 54. Canada Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 55. Canada Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 56. Canada Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 57. Canada Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 58. Canada Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 59. Canada Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 60. Canada Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 61. Canada Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 62. Canada Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 63. Canada Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 64. Mexico Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 65. Mexico Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 66. Mexico Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 67. Mexico Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 68. Mexico Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 69. Mexico Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 70. Mexico Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 71. Mexico Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 72. Mexico Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 73. Mexico Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 74. Mexico Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 75. Mexico Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 76. Mexico Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 77. Europe Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 78. Europe Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 79. Europe Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 80. Europe Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 81. Europe Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 82. Europe Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 83. Europe Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 84. Europe Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 85. Europe Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 86. Europe Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 87. Europe Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 88. Europe Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 89. Europe Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 90. UK Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 91. UK Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 92. UK Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 93. UK Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 94. UK Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 95. UK Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 96. UK Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 97. UK Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 98. UK Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 99. UK Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 100. UK Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 101. UK Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 102. UK Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 103. Germany Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 104. Germany Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 105. Germany Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 106. Germany Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 107. Germany Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 108. Germany Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 109. Germany Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 110. Germany Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 111. Germany Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 112. Germany Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 113. Germany Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 114. Germany Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 115. Germany Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 116. France Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 117. France Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 118. France Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 119. France Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 120. France Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 121. France Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 122. France Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 123. France Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 124. France Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 125. France Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 126. France Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 127. France Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 128. France Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 129. Spain Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 130. Spain Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 131. Spain Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 132. Spain Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 133. Spain Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 134. Spain Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 135. Spain Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 136. Spain Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 137. Spain Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 138. Spain Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 139. Spain Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 140. Spain Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 141. Spain Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 142. Italy Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 143. Italy Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 144. Italy Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 145. Italy Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 146. Italy Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 147. Italy Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 148. Italy Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 149. Italy Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 150. Italy Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 151. Italy Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 152. Italy Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 153. Italy Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 154. Italy Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 155. Denmark Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 156. Denmark Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 157. Denmark Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 158. Denmark Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 159. Denmark Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 160. Denmark Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 161. Denmark Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 162. Denmark Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 163. Denmark Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 164. Denmark Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 165. Denmark Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 166. Denmark Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 167. Denmark Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 168. Sweden Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 169. Sweden Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 170. Sweden Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 171. Sweden Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 172. Sweden Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 173. Sweden Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 174. Sweden Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 175. Sweden Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 176. Sweden Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 177. Sweden Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 178. Sweden Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 179. Sweden Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 180. Sweden Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 181. Norway Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 182. Norway Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 183. Norway Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 184. Norway Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 185. Norway Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 186. Norway Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 187. Norway Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 188. Norway Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 189. Norway Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 190. Norway Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 191. Norway Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 192. Norway Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 193. Norway Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 194. Asia Pacific Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 195. Asia Pacific Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 196. Asia Pacific Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 197. Asia Pacific Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 198. Asia Pacific Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 199. Asia Pacific Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 200. Asia Pacific Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 201. Asia Pacific Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 202. Asia Pacific Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 203. Asia Pacific Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 204. Asia Pacific Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 205. Asia Pacific Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 206. Asia Pacific Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 207. Japan Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 208. Japan Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 209. Japan Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 210. Japan Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 211. Japan Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 212. Japan Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 213. Japan Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 214. Japan Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 215. Japan Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 216. Japan Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 217. Japan Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 218. Japan Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 219. Japan Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 220. China Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 221. China Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 222. China Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 223. China Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 224. China Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 225. China Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 226. China Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 227. China Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 228. China Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 229. China Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 230. China Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 231. China Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 232. China Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 233. India Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 234. India Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 235. India Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 236. India Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 237. India Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 238. India Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 239. India Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 240. India Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 241. India Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 242. India Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 243. India Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 244. India Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 245. India Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 246. Australia Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 247. Australia Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 248. Australia Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 249. Australia Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 250. Australia Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 251. Australia Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 252. Australia Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 253. Australia Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 254. Australia Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 255. Australia Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 256. Australia Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 257. Australia Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 258. Australia Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 259. Thailand Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 260. Thailand Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 261. Thailand Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 262. Thailand Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 263. Thailand Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 264. Thailand Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 265. Thailand Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 266. Thailand Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 267. Thailand Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 268. Thailand Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 269. Thailand Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 270. Thailand Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 271. Thailand Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 272. South Korea Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 273. South Korea Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 274. South Korea Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 275. South Korea Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 276. South Korea Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 277. South Korea Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 278. South Korea Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 279. South Korea Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 280. South Korea Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 281. South Korea Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 282. South Korea Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 283. South Korea Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 284. South Korea Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 285. Latin America Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 286. Latin America Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 287. Latin America Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 288. Latin America Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 289. Latin America Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 290. Latin America Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 291. Latin America Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 292. Latin America Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 293. Latin America Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 294. Latin America Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 295. Latin America Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 296. Latin America Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 297. Latin America Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 298. Brazil Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 299. Brazil Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 300. Brazil Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 301. Brazil Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 302. Brazil Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 303. Brazil Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 304. Brazil Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 305. Brazil Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 306. Brazil Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 307. Brazil Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 308. Brazil Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 309. Brazil Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 310. Brazil Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)